Medicom Health
  • Solutions
    • Health Risk Assessments (HRAs)
    • Follow-Up & Nurturing
    • Promotional Services
    • Self-Care Planners
    • Rx Savings Assistant
    • Close
  • Articles
  • Company
  • Support
    • Client Portal Log-In
    • Tips & Support
    • Contact Support
    • Close
  • Contact Us
  • Most Recent
  • Blog & News
  • Events & Webinars
  • Case Studies
  • Tips & Support

Novel cholesterol fighters efficacy data presented at AHA Scientific Sessions

November 8, 2012 / Tony Huth / Blog, News

Approximately 18,000 global health professionals specializing in cardiovascular medicine and research converged on Los Angeles this past week for the annual American Heart Association Scientific Sessions.

Perhaps the biggest news from the Sessions was the presentation of data for a new class of cholesterol-lowering agents called PCSK9 protein blockers. Several of the world’s foremost Biopharma companies such as Amgen, Pfizer, Sanofi and its partner, Regeneron Pharmaceuticals, each have their own PCSK9 product under development. These extremely potent products lower LDL (the bad cholesterol) by 50% or more and will need to be administered via injection. The science behind the new products is that they block the PCSK9 protein, which interferes with the liver’s ability to clear LDL cholesterol from the blood.

There is a huge potential market for this new class of drugs, factoring the 71 million Americans who have high LDL cholesterol and only about 1/3 of them are adequately controlled, typically managed with statin therapy. This leaves nearly 48 million Americans who need better LDL cholesterol management; and may need this type of therapy if statins do not work well enough.

Sanofi/Regeneron has begun enrolling patients in Phase III Clinical Trials, while Amgen and Pfizer are likely to initiate similar trials in the near future. The theory behind any drug that lowers LDL cholesterol (or an agent that raises HDL cholesterol) is that they will lower the person’s heart attack risk. To learn YOUR heart attack risk, and see how modifying cholesterol levels impact your 10-year risk, click here.

Facebook0Twitter0Google plus0

Self-Guided Demos

View Product Demos

Learn more about “v3” HRAs

Subscribe to News

Thank you!

Thank you for subscribing to Medicom Health News.


Convert Web Visits into Office Visits

marketing-sheet-thumb

Download PDF


Related Articles

Letter from the Founder

Fighting Readmission and Improving Adherence for FREE

Medicom Health Announces Record Second Quarter 2016

Minneapolis/St. Paul Business Journal Adds Medicom Health to Its 2011 “Fast 50″ List of Minnesota’s Fastest-Growing Companies

Data-Driven Marketing For Healthcare

Please do not hesitate to contact us with questions, comments, requests, feedback, etc.

Site Highlights

  • Health Risk Assessments (HRAs)
  • Rx Savings Assistant
  • Case Studies
  • HRA Promotion
  • Self-Care Planners
  • Partnerships

Recent Articles

  • data-driven marketing

    Data-Driven Marketing For Healthcare

  • sticky CTAs

    Are Your CTAs “Sticky” Enough?

  • healthcare digital marketing trends survey

    Recommendation: 2019 Healthcare Digital Marketing Trends Survey

  • hra-creation

    Benefits of Using a Pre-Built Solution vs. Creating Your Own

  • ah-ha moments foster health behavior change

    Patient Nurturing: Foster Ah-ha Moments to Encourage Health Behavior Change

  • hitrust-security

    HITRUST Security Changes

Medicom Health

400 First Avenue North, Suite 550
Minneapolis, MN 55401 USA

Contact

  • (800) 971-0785
  • Contact Us
    • Facebook
    • Linkedin
    • Twitter
© 2019 Medicom Health
  • Back to top

What do we mean by “HRA?”

HRA stands for “Health Risk Assessment.”

At their simplest, HRAs ask health related questions and apply algorithms to calculate results to stratify users into groups.

The most popular type of HRAs are those used by health insurance companies.

They often use clunky, lengthy annual HRAs to quickly gather self-reported health metrics and determine how much you might cost them over time. They are not typically designed to help the individual take concrete action.

Our HRAs are different:

  • They are designed specifically to educate and motivate users about a specific health concern.
  • They have very tailored recommendations for next steps which can be edited in the Admin Portal.
  • They are designed to be used on a mobile device– quickly and conveniently.

We believe if you make it easy for users to educate and motivate themselves, they will willingly opt-in to your messaging.